Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.41
−$0.44 · -23.78%
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
Previous close
$1.41
−$0.44 · -23.78%
After-hours
$1.4515
+$0.0415 · +2.94%
Oct 9, 7:59 PM ET
Regular session · ET · Market data may be delayed.
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
Day range
Current $1.41
52-week range
Current $1.41
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
58
Mixed
Risk
51
Elevated Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
Day range
Current $1.41
52-week range
Current $1.41
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 111.64K USD | — | — | 18.02K USD |
| Gross profit | — | −111.64K USD | — | — | −18.02K USD |
| Research and development | 574.94K USD | 175K USD | 2.42M USD | 9.16M USD | 856.82K USD |
| Selling, general, and administrative | 1.83M USD | 3.63M USD | 2.23M USD | 3.28M USD | 2.05M USD |
| Operating expenses | 3.26M USD | 3.81M USD | 6.05M USD | 12.43M USD | 3.66M USD |
| Interest income | 41.87K USD | 116.05K USD | 253.54K USD | 140.25K USD | — |
| Interest expense | — | — | — | — | 5.63K USD |
| Depreciation and amortization | 112.12K USD | 117.27K USD | 139.69K USD | 74.87K USD | 17.64K USD |
| Operating income | −3.26M USD | −3.92M USD | −6.05M USD | −12.43M USD | −3.68M USD |
| Net income | −2.66M USD | −3.15M USD | −2.16M USD | −10.45M USD | −1.66M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 6, 2026 | 1:5 | — | — |
Stock split | Nov 14, 2023 | 1:9 | — | — |
Stock split | Sep 23, 2021 | 1:12 | — | — |
Effective Apr 6, 2026
1:5
Effective Nov 14, 2023
1:9
Effective Sep 23, 2021
1:12
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
